Tokyo (JCNN) - DNAVEC, a Tsukuba-based bio venture company, announced on June 9 that it has launched a joint research project with the National Center for Geriatrics and Gerontology for a nasal spray vaccine for Alzheimer’s disease. Specifically, the company will collaborate with the National Institute for Longevity Sciences, a research arm of the center. Using Sendai Virus Vectors (SeV), DNAVEC’s proprietary vector that develops amyloid-beta, a kind of protein that plays a role in the generation of plaques, the two partners will strive to develop a nasal spray vaccine that helps reduce senile plaques in the brain.
